Shay Capital’s Avalo Therapeutics AVTX Stock Holding History

Shay Capital’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,166	Closed	-$152K	–	501
2026 Q1	$152K	Buy	+10,166	New	+$159K	0.01%	411

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Shay Capital's AVTX Position: Q2 2026 in Review

Shay Capital sold out of Avalo Therapeutics (AVTX) in Q2 2026, closing a stake of 10,166 shares — an estimated $152K sold.

Shay Capital first reported a position in AVTX in Q1 2026 and held it in 1 quarter. The position peaked at $152K in Q1 2026. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

Shay Capital reported no remaining Avalo Therapeutics position as of Q2 2026 after selling out during the quarter.
Shay Capital sold 10,166 Avalo Therapeutics shares in Q2 2026, an estimated $152K.
Shay Capital first reported a position in Avalo Therapeutics in Q1 2026 and held it in 1 quarter.
Shay Capital's Avalo Therapeutics position peaked at $152K in Q1 2026.
126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Shay Capital's 13F filing for Q2 2026, filed 14 Aug 2026.